Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ian Walters"'
Autor:
Eric Assenat, Ian Walters, Joong-Won Park, Josep M. Llovet, Masatoshi Kudo, Jean-Luc Raoul, Ferran Torres, H. Y. Lim, Charissa Chang, Eveline Boucher, Riccardo Lencioni, Valérie Boige, Yoon-Koo Kang, Thomas Decaens
Publikováno v:
Journal of Clinical Oncology. 33:4084-4084
4084 Background: mRECIST (modified Response Evaluation Criteria In Solid Tumors) was developed to overcome the limitations of standard RECIST in hepatocellular carcinoma (HCC) response assessment. Retrospective studies have correlated objective respo
Autor:
John Simes, Dongsheng Tu, Asif Shaikh, Lillian L. Siu, David Wyld, Warren Joubert, O'Callaghan. Christopher J., Malcolm J. Moore, Ian Walters, Craig Underhill, Penny Phillips, Benoit Samson, Timothy J. Price, Michelle F. Cronk, Antonino Bonaventura, Brian Peter Findlay, Jeremy Shapiro, Catherine Doyle, Derek J. Jonker, John Zalcberg
Publikováno v:
Journal of Clinical Oncology. 30:3572-3572
3572 Notice of Retraction: "Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts
Autor:
Andrew Haydon, Louise M. Nott, Timothy J. Price, John Simes, Michael B. Sawyer, Danielle Charpentier, Malcolm J. Moore, Derek J. Jonker, Jeremy Shapiro, Nadine M Magoski, Jehan Siddiqui, Christos S. Karapetis, Michael Jefford, Lillian L. Siu, John Zalcberg, Ian Walters, Christopher J. O'Callaghan, Winston Liauw, Félix Couture, Dongsheng Tu
Publikováno v:
Journal of Clinical Oncology. 30:3504-3504
3504 Background: The anti-EGFR monoclonal antibody CET has improved survival in pts with chemotherapy refractory, K-RAS WT mCRC. BRIV is a potent inhibitor of multiple receptor tyrosine kinases including both VEGFR and FGFR. The combination of CET an
Autor:
Ovidiu C. Trifan, Allen C. Chen, Ian Walters, Hervé Lena, Eugene Henry Paschold, Giorgio Cruciani, Glen Laird, Julien Mazieres
Publikováno v:
Journal of Clinical Oncology. 30:7584-7584
7584 Background: CT- 322 is a pegylated protein engineered from the tenth type III human fibronectin domain thatspecifically blocks VEGFR-2 signaling by all known ligands. This international randomized study assessed the efficacy and safety of PC + C
Autor:
Andrew Strickland, Christopher J. O'Callaghan, Fabyolla El-Tahche, Jennifer Shannon, Derek J. Jonker, Heather-Jane Au, Lillian L. Siu, Jeremy Shapiro, Muhammad Salim, Ian Walters, Malcolm J. Moore, Rami Kotb, John Zalcberg, Mark Jeffery, Dongsheng Tu, Jacob C. Easaw, Jolie Ringash, Sabe Sabesan, Siobhan Ng, Thierry Alcindor
Publikováno v:
Journal of Clinical Oncology. 30:542-542
542 Background: The CO.20 trial randomized pts with K-RAS WT chemotherapy refractory mCRC to receive CET + BRIV (Arm A) or CET + placebo (Arm B). Although overall survival (primary endpoint) was not significantly improved (HR=0.88, p=0.12) in this he
Autor:
M. Savoie, Timothy J. Price, John Zalcberg, Jolie Ringash, P. Smith, D. Nomikos, Nadine M Magoski, Nicole Mittmann, Jeremy Shapiro, Fabyolla El-Tahche, Dongsheng Tu, Malcolm J. Moore, Shakeel Virk, Liting Zhu, Christopher J. O'Callaghan, R. Gill, L.L. Siu, Derek J. Jonker, Ian Walters, John Simes
Publikováno v:
Journal of Clinical Oncology. 29:TPS163-TPS163
TPS163 Background: While anti-EGFR monoclonal antibody, CET, improves survival in KRAS WT chemotherapy refractory aCRC, dual biologic strategies may overcome observed resistance to therapy. BRIV is...